Clarkston Capital Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Clarkston Capital Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-11,493	Closed	-$715K	–	133
2014 Q2	$715K	Buy	11,493 +1,000	+10%	+$60.4K	0.13%	94
2014 Q1	$716K	Hold	10,493	–	–	0.14%	94
2013 Q4	$738K	Hold	10,493	–	–	0.29%	68
2013 Q3	$757K	Buy	+10,493	New	+$697K	0.37%	64

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Clarkston Capital Partners's BMRN Position: Q3 2014 in Review

Clarkston Capital Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2014, closing a stake of 11,493 shares — an estimated $715K sold.

Clarkston Capital Partners first reported a position in BMRN in Q3 2013 and held it in 4 quarters. The position peaked at $757K in Q3 2013. 316 funds tracked by Wall St. Rank hold BMRN as of Q3 2014.

Clarkston Capital Partners reported no remaining BioMarin Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
Clarkston Capital Partners sold 11,493 BioMarin Pharmaceuticals shares in Q3 2014, an estimated $715K.
Clarkston Capital Partners first reported a position in BioMarin Pharmaceuticals in Q3 2013 and held it in 4 quarters.
Clarkston Capital Partners's BioMarin Pharmaceuticals position peaked at $757K in Q3 2013.
316 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2014.

Based on Clarkston Capital Partners's 13F filing for Q3 2014, filed 14 Oct 2014.